Glytec Secures $36M to Revolutionize Diabetes Management with Its FDA-Cleared, AI-Driven SaaS Platform

Glytec is thrilled to announce a significant milestone in our journey toward transforming diabetes management: we have successfully raised $36,000,000 to further enhance our industry-leading SaaS platform. Trusted by over 350 hospitals nationwide, Glytec’s innovative technology empowers collaborative diabetes management and advanced insulin dosing, continuously improving patient outcomes, reducing readmissions, and streamlining clinical workflows. This robust funding round is a testament to the strength of our mission and the proven value of our solutions, including the Glytec Glucommander®—the first-ever FDA-cleared cloud-based insulin management software. Fully EMR-integrated, our platform offers seamless implementation and is underpinned by clinical decision support, proactive workflow alerts, comprehensive patient monitoring, identification of at-risk individuals, and AI-driven analytics, setting a new standard in healthcare technology. The capital infusion will be strategically allocated toward accelerating our research and development efforts, expanding our clinical partnerships, and further augmenting our platform’s capabilities. With validation derived from 106 patents and over 100 publications, Glytec is uniquely positioned to continue its mission of promoting health equity and improving diabetes outcomes from hospital to home. Our dedicated, mission-driven team remains committed to supporting healthcare leaders and clinicians with tools that deliver an impressive 6-8x ROI, while enabling healthcare systems to provide exceptional, patient-centric care in the fight against diabetes. We invite our community, future partners, and supporters to join us on this exciting journey as we leverage this new funding to expand our impact and drive innovations in diabetes management. For more information, follow Glytec on X (@Glytec) or visit www.Glytec.com.